Aim To investigate the effect of rosuvastatin calcium combined with metformin on coronary artery stent restenosis after coronary intervention in patients with coronary heart disease (CHD). Methods 218 patients with coronary artery disease after stenting were divided into observation group (109 cases) and control group (109 cases) according to the random number table method. The control group were treated with rosuvastatin calcium 20 mg and routine treatment, the observation group was treated with rosuvastatin calcium (20 mg) combined with metformin (250 mg, Bid) on the basis of conventional treatment, after 1 year of treatment, coronary stent restenosis rate and the incidence of abnormal blood glucose were compared between the two groups. Results Coronary artery stent restenosis rate was 2.9% (3/103) and 12.0% (12/100), new onset diabetes ratio was 5.8% (6/103) and 15.0% (15/100), new onset diabetes impaired were 4.9%(5/103) and 18.0%(18/100) in patients of observation group and control group, the difference was statistically significant (P＜0.05). The blood lipid compliance rate of the observation group was significantly higher than that of the control group(56.0% vs 43.0%), especially TG, the difference was statistically significant compared with the control group(P＜0.01).Conclusion In patients with coronary heart disease after percutaneous coronary intervention, rosuvastatin combined with metformin can significantly reduce coronary artery stent restenosis rate, and does not increase the incidence of diabetes, hypoglycemia incidence. There was no significant difference in the effect on renal function compared with control group.